ImmunityBio, Inc. (IBRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 60M 120M 180M Q3 '24: 7.3M Q4 '24: 14.7M Q1 '25: 31.2M Q2 '25: 56.6M Q3 '25: 82.6M Q4 '25: 113.3M Q1 '26: 141M Q2 '26: 165.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

0 60M 120M 180M Q3 '24: 7.3M Q4 '24: 14.7M Q1 '25: 31.2M Q2 '25: 56.4M Q3 '25: 82.2M Q4 '25: 112.5M Q1 '26: 140M Q2 '26: 164.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '24: -360.2M Q4 '24: -344.2M Q1 '25: -313.4M Q2 '25: -285.4M Q3 '25: -260.7M Q4 '25: -256M Q1 '26: -261.4M Q2 '26: -251.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-1.1B -700M -350M 0 350M 700M 1.1B Q3 '24: -587.8M Q4 '24: -413.6M Q1 '25: -409.1M Q2 '25: -367.1M Q3 '25: -348.6M Q4 '25: -351.4M Q1 '26: -854.5M Q2 '26: -992.4M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 400K 800K 1.2M Q3 '24: 0 Q4 '24: 0 Q1 '25: 58K Q2 '25: 194K Q3 '25: 371K Q4 '25: 753K Q1 '26: 933K Q2 '26: 1.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '24: -421.4M Q4 '24: -391.2M Q1 '25: -370.2M Q2 '25: -349.6M Q3 '25: -319.7M Q4 '25: -304.9M Q1 '26: -294.4M Q2 '26: -281.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '24: -434.1M Q4 '24: -398.1M Q1 '25: -376.9M Q2 '25: -356.7M Q3 '25: -324.8M Q4 '25: -308.8M Q1 '26: -298.9M Q2 '26: -288.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 400M 800M 1.2B Q1 '24: 672.8M Q2 '24: 686.9M Q3 '24: 698M Q1 '25: 853.2M Q2 '25: 888.2M Q3 '25: 946.6M Q1 '26: 1B Q2 '26: 1.1B Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.05 -0.70 -0.35 0.00 0.35 0.70 1.05 Q3 '24: -0.92 Q4 '24: -0.63 Q1 '25: -0.58 Q2 '25: -0.48 Q3 '25: -0.41 Q4 '25: -0.38 Q1 '26: -0.85 Q2 '26: -0.97 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.